Bicara Therapeutics Inc. ... (BCAX)
Bicara Therapeutics Common Stock Statistics
Share Statistics
Bicara Therapeutics Common Stock has 54.54M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 54.54M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | 85.26% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 179 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -43.05 and the forward PE ratio is -4.93. Bicara Therapeutics Common Stock's PEG ratio is 0.72.
| PE Ratio | -43.05 |
| Forward PE | -4.93 |
| PS Ratio | 0 |
| Forward PS | 4 |
| PB Ratio | 5.95 |
| P/FCF Ratio | -39.13 |
| PEG Ratio | 0.72 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Bicara Therapeutics Common Stock.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 27.93, with a Debt / Equity ratio of 0.
| Current Ratio | 27.93 |
| Quick Ratio | 27.93 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,236,272.73 |
| Employee Count | 55 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 187K |
| Effective Tax Rate | -0.28% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is -1.49, so Bicara Therapeutics Common Stock's price volatility has been lower than the market average.
| Beta | -1.49 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 13.06 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 59.63 |
| Average Volume (20 Days) | 572,395 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -82.39M |
| Net Income | -68M |
| EBITDA | -82.39M |
| EBIT | -67.81M |
| Earnings Per Share (EPS) | -0.4 |
Balance Sheet
The company has 489.71M in cash and 738K in debt, giving a net cash position of 488.97M.
| Cash & Cash Equivalents | 489.71M |
| Total Debt | 738K |
| Net Cash | 488.97M |
| Retained Earnings | -221.02M |
| Total Assets | 510M |
| Working Capital | 484.54M |
Cash Flow
In the last 12 months, operating cash flow was -74.75M and capital expenditures -71K, giving a free cash flow of -74.82M.
| Operating Cash Flow | -74.75M |
| Capital Expenditures | -71K |
| Free Cash Flow | -74.82M |
| FCF Per Share | -0.45 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BCAX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BCAX is $33, which is 123.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $33 |
| Price Target Difference | 123.1% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 26.74 |
| Piotroski F-Score | 1 |